(Q41234743)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25765543%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25765543%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25765543%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Fotios Polydoros

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25765543%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

R J Harris

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25765543%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

A K Holcroft

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25765543%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

L J Scott

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25765543%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

N Carmell

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25765543%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

E McDonald

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25765543%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

R E Clark

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25765543%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

13 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25765543%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25765543%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25765543%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25765543%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

1514-1523

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25765543%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2015.71

2 March 2020

exact match

0 references

cites work

The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

CIP2A is associated with human breast cancer aggressivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

CIP2A inhibits PP2A in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

CIP2A is a target of bortezomib in human triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

CIP2A protein expression in high-grade, high-stage bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Dominant negative MYC blocks transformation by ABL oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

[Expression of Bcl-2 protein and the amplification of c-myc gene in patients with chronic myeloid leukemia].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

The ever expanding role for c-Myc in promoting genomic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

The dark side of E2F1: in transit beyond apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Mouse development with a single E2F activator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Evolving intricacies and implications of E2F1 regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

p53 and E2f: partners in life and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

The biology of CML blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

p53 in chronic myelogenous leukemia in acute phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

CIP2A increases self-renewal and is linked to Myc in neural progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Impaired DNA replication within progenitor cell pools promotes leukemogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.71

The p120-v-Abl protein interacts with E2F-1 and regulates E2F-1 transcriptional activity

21 January 2018

1 reference

12 December 2020

CIP2A expression is elevated in cervical cancer

1 reference

12 December 2020

Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells.

1 reference

12 December 2020

IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma.

1 reference

12 December 2020

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

1 reference

12 December 2020

c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia

1 reference

12 December 2020

Detection of trisomy 8 in philadelphia chromosome-positive CML patients using conventional cytogenetic and interphase fluorescence in situ hybridization techniques and its relation to c-myc involvement

1 reference

12 December 2020

Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation

1 reference

12 December 2020

Clinical implications of CIP2A protein expression in breast cancer

1 reference

12 December 2020

Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia

1 reference

12 December 2020